2018 was a gangbuster year for VC-funding into startups, reaching levels not seen since the height of the dot-com and genomics era.
January 16, 2019 | LifeSciVC
Venture Volatility: 2018’s Banner Year Closed Cautiously
January 14, 2019 | LifeSciVC
The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference
Another year, another JPM week. With a weekend to recuperate and reflect, I come away more concerned than ever about JPM and our industry.
January 4, 2019 | News
Atlas Venture’s 2018 Year in Review
2018 was an active and exciting year in the Atlas portfolio. Six of our portfolio companies went public, the drug developed by Arteaus was approved, we announced our first Opportunity Fund, and so much more. Check out our newsletter for the highlights.
January 3, 2019 | LifeSciVC
Biotech IPO Market: Closing The Books On 2018’s Crazy Year
2018 was an incredible boom year in the number of new biotech offerings, with 60 IPOs on US exchanges. But as we’re all painfully aware, after the overall biotech market ($XBI) touched its all-time high in August, the last third of the year was challenging – indices plummeting over 25% in four months.
January 2, 2019 | News
Hurricane Lantus: The Storm That Will Finally Force Pharma to Take Cost-Effectiveness and Budgetary Impact Seriously
“It just says ‘High.'”
I winced. My patient, a man with type 1 diabetes who had emigrated from Latin America two weeks earlier, was reading a finger prick result on his blood sugar meter to me over the phone. Normal blood sugar ranges between 70 and 100. Beyond 600, the meter loses accuracy and spits out an understated “High” instead of an actual number. I knew what this seemingly innocuous message meant: My patient was at risk for serious, even deadly complications from a critically high blood sugar. And I had known there was a chance his blood sugar would spike when I switched his insulin regimen.